These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15164519)

  • 1. [Efficacy of plague prophylaxis with streptomycin, tetracycline, and rifampicin in simultaneous immunization of white mice by resistant EV NRIEG strain].
    Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI
    Antibiot Khimioter; 2004; 49(1):17-21. PubMed ID: 15164519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of outcomes of combined specific prophylaxis with the antibiotic resistant immunogenic plague pathogen strain and emergency prophylaxis with aminoglycosides in the experimental plague model in white mice].
    Ryzhko IV; Tsuraeva RI; Moldavan IA; Shcherbaniuk AI; Shut'ko AG
    Antibiot Khimioter; 2003; 48(5):15-9. PubMed ID: 12968464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of monoclonal antibodies to plague microbe antigens at the early stage of infection in white mice for enhancement of the late streptomycin and doxycycline treatment].
    Ryzhko IV; Tsuraeva RI; Alekseeva LP; Shcherbaniuk AI; Mishan'kin MB
    Antibiot Khimioter; 2003; 48(3):21-5. PubMed ID: 12914117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylactic use of ceftriaxone in combination with F I antigen immunization in studies on uninbred albino mice infected by Yersinia pestis. Antiplague immunity development].
    Ryzhko IV; Moldavan IA; Tsuraeva RI; Shcherbaniuk AI
    Antibiot Khimioter; 2006; 51(9-10):8-12. PubMed ID: 18030785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of rifampicin in experimental plague infection].
    Makarovskaia LN; Shcherbaniuk AI; Bugaeva OK
    Antibiot Khimioter; 1993 Jul; 38(7):34-6. PubMed ID: 8161275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Synergistic action of some antibacterial agents in studies on albino mice with experimental plague caused by Fr- phenotype strain of the plague microbe].
    Shcherbaniuk AI; Liukshina EIu; Ryzhko IV; Smorodinova IuV
    Antibiot Khimioter; 2006; 51(1):7-10. PubMed ID: 16734358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The experimental validation of the advantages of combined emergency (fluoroquinolones) and specific (EV Nalr) prevention of plague versus their sequential use].
    Ryzhko IV; Tsuraeva RI; Samokhodkina ED; Shcherbaniuk AI; Mishan'kin BN; Koroleva NS; Anisimov BN
    Antibiot Khimioter; 2000; 45(7):10-3. PubMed ID: 10987101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Formation of virulent antigen-modified mutants (Fra-, Fra-Tox-) of plague bacteria resistant to rifampicin and quinolones].
    Ryzhko IV; Shcherbaniuk AI; Skalyga EIu; Tsuraeva RI; Moldavan IA
    Antibiot Khimioter; 2003; 48(4):19-23. PubMed ID: 13677133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the effectiveness of antibacterial substances in treating an experimental form of bubonic plague in monkeys].
    Romanov VE; Evstigneev VI; Vasil'ev NT; Shabalin BA; Paramonov VE
    Antibiot Khimioter; 2001; 46(8):6-8. PubMed ID: 11871319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ofloxacin efficacy in the prophylaxis and treatment of experimental plague due to antigen complete and defective strains of the pathogen].
    Samokhodkina ED; Shcherbaniuk AI; Ryzhko IV; Tsuraeva RI; Skalyga EIu
    Antibiot Khimioter; 2002; 47(3):26-9. PubMed ID: 16127904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Isepamycin in prophylaxis and treatment of experimental plague due to FI+ and FI- variants of plague microbe].
    Smorodinova IuV; Shcherbaniuk AI; Ryzhko IV; Moldavan IA
    Antibiot Khimioter; 2005; 50(8-9):23-6. PubMed ID: 17016907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in new Mexico, 1985-1999.
    Boulanger LL; Ettestad P; Fogarty JD; Dennis DT; Romig D; Mertz G
    Clin Infect Dis; 2004 Mar; 38(5):663-9. PubMed ID: 14986250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postexposure Administration of a Yersinia pestis Live Vaccine for Potentiation of Second-Line Antibiotic Treatment Against Pneumonic Plague.
    Zauberman A; Gur D; Levy Y; Aftalion M; Vagima Y; Tidhar A; Chitlaru T; Mamroud E
    J Infect Dis; 2019 Aug; 220(7):1147-1151. PubMed ID: 31095689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy.
    Louie A; Deziel MR; Liu W; Drusano GL
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2661-7. PubMed ID: 17517837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
    Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
    Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Doxycycline in the prevention of experimental plague induced by plague microbe variants].
    Samokhodkina ED; Ryzhko IV; Shcherbaniuk AI; Kasatkina IV; Tsuraeva RI; Zhigalova TA
    Antibiot Khimioter; 1992 Nov; 37(11):26-8. PubMed ID: 1300930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmid-mediated doxycycline resistance in a Yersinia pestis strain isolated from a rat.
    Cabanel N; Bouchier C; Rajerison M; Carniel E
    Int J Antimicrob Agents; 2018 Feb; 51(2):249-254. PubMed ID: 29030266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro efficacy of antibiotics commonly used to treat human plague against intracellular Yersinia pestis.
    Wendte JM; Ponnusamy D; Reiber D; Blair JL; Clinkenbeard KD
    Antimicrob Agents Chemother; 2011 Aug; 55(8):3752-7. PubMed ID: 21628541
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Steenbergen J; Tanaka SK; Miller LL; Halasohoris SA; Hershfield JR
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.